Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Topical Balm Reduces Taxane-Related Nail Damage

      June 12, 2017
      By Lisa Schulmeister, RN, MN, APRN-BC, FAAN
      Article

      A recent study has found that a topical nail bed balm may be effective in preventing and mitigating nail damage, a common adverse effect from taxane chemotherapy.

      A group of researchers in the United Kingdom evaluated the effectiveness of a natural nail balm in preventing or mitigating nail damage, which is a common adverse effect of taxane chemotherapy. They investigated whether a topical nail bed balm containing bioactive, polyphenolic-rich, African salvia officinalis and gaultheria procumbens in a natural base of olea europaea, butyrospermun parkii, cera alba, and theobroma cacao protected the nail beds. This natural nail balm has reported anti-inflammatory, analgesic, antioxidant, and antimicrobial properties.

      Sixty patients (23 male, 37 female) were randomized to apply the natural balm or a scented petroleum balm (placebo control) to the nailbeds 3 times a day during treatment. There were no differences among patient demographics, and type and number of chemotherapy cycles between the 2 groups (all patients received taxanes). At baseline and at the end of chemotherapy treatment, both patients and physicians measured nail health outcomes. Patients completed a Dermatology Life Quality questionnaire and a linear severity scale, and physicians completed a Nail Psoriasis Index (NPSI) and a linear severity scale based on clinical examination and photographs.

      The polyphenolics-rich essential oils and plant-based waxes in the natural nail bed balm significantly reduced chemotherapy-related nail damage and improved nail-related quality of life compared with the plain petroleum-based balm. The researchers recommend additional research, including studying the effect of combining the natural nail bed balm with nail bed cooling. Study findings were presented during a poster session at the 2017 ASCO Annual Meeting and are available here.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman wearing a patterned shirt in front of a dark blue background
      Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
      3 experts in this video
      3 experts in this video
      Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
      Related Content

      Photo of a nurse recording data on a computer and tablet

      The Evolving Role of the Oncology Nurse in Clinical Trials

      Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN
      June 14th 2025
      Article

      Oncology nurses are paramount to the success of patients, especially through their work on clinical trials.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Photo of an APP talking to and empowering a patient

      Case Study: Bridging the Gap for Patients With Metastatic CRC

      Randi Kihnel, MSN, APRN, ACCNS-AG
      June 13th 2025
      Article

      Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic of a clipboard that reads "FDA"

      Zanubrutinib Tablets Greenlit by FDA for All Approved Indications

      Bridget Hoyt
      June 12th 2025
      Article

      An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and Waldenström macroglobulinemia.


      Photo of the FDA building

      FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC

      Bridget Hoyt
      June 12th 2025
      Article

      UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

      Related Content

      Photo of a nurse recording data on a computer and tablet

      The Evolving Role of the Oncology Nurse in Clinical Trials

      Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN
      June 14th 2025
      Article

      Oncology nurses are paramount to the success of patients, especially through their work on clinical trials.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Photo of an APP talking to and empowering a patient

      Case Study: Bridging the Gap for Patients With Metastatic CRC

      Randi Kihnel, MSN, APRN, ACCNS-AG
      June 13th 2025
      Article

      Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic of a clipboard that reads "FDA"

      Zanubrutinib Tablets Greenlit by FDA for All Approved Indications

      Bridget Hoyt
      June 12th 2025
      Article

      An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and Waldenström macroglobulinemia.


      Photo of the FDA building

      FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC

      Bridget Hoyt
      June 12th 2025
      Article

      UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

      Latest Conference Coverage

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.